MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
10.14
-0.51
-4.74%
After Hours: 10.37 +0.23 +2.27% 17:46 06/14 EDT
OPEN
10.53
PREV CLOSE
10.65
HIGH
10.57
LOW
10.13
VOLUME
1.67M
TURNOVER
0
52 WEEK HIGH
14.57
52 WEEK LOW
9.02
MARKET CAP
3.00B
P/E (TTM)
-20.5638
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FOLD last week (0603-0607)?
Weekly Report · 6d ago
Amicus Therapeut: Statement of changes in beneficial ownership of securities
Press release · 06/08 00:07
Weekly Report: what happened at FOLD last week (0527-0531)?
Weekly Report · 06/03 10:04
3 Biotech Names Under $10 I Own
Bret Jensen owns three biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability. The other is cash rich and has several partnerships with large pharma companies. Amicus Therapeutics, Inc. And Aurinia Pharmaceuticals Inc. Are among the names he owns in his portfolio.
Seeking Alpha · 06/02 14:18
Validea Detailed Fundamental Analysis - FOLD
NASDAQ · 05/31 20:11
Wells Fargo Initiates Coverage of Amicus Therapeutics (FOLD) with Overweight Recommendation
NASDAQ · 05/31 00:13
Amicus Therapeutics Initiated at Overweight by Wells Fargo
Dow Jones · 05/30 15:17
Amicus Therapeutics Price Target Announced at $18.00/Share by Wells Fargo
Dow Jones · 05/30 15:17
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.